{"id":"NCT00351468","sponsor":"Novartis Pharmaceuticals","briefTitle":"EXTEND (Eltrombopag Extended Dosing Study)","officialTitle":"EXTEND (Eltrombopag Extended Dosing Study): An Extension Study of Eltrombopag Olamine (SB-497115-GR) in Adults, With Idiopathic Thrombocytopenic Purpura (ITP), Previously Enrolled in an Eltrombopag Study.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-06","primaryCompletion":"2015-07","completion":"2015-07","firstPosted":"2006-07-12","resultsPosted":"2017-04-17","lastUpdate":"2017-04-17"},"enrollment":302,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Purpura, Thrombocytopaenic, Idiopathic"],"interventions":[{"type":"DRUG","name":"eltrombopag olamine (SB-497115-GR)","otherNames":[]}],"arms":[{"label":"Eltrombopag","type":"EXPERIMENTAL"}],"summary":"An open-label, dose-adjustment, extension study to evaluate the safety and efficacy of eltrombopag for the treatment of subjects with idiopathic thrombocytopenic purpura (ITP) who have previously been enrolled in an eltrombopag trial. This study will allow adjustment of the eltrombopag dose to achieve an individualized dose and schedule for each subject. In addition, the ability to reduce the dose of concomitant ITP medications in the presence of eltrombopag, while maintaining platelet counts = 50,000/Î¼L will be investigated.","primaryOutcome":{"measure":"Overall Summary of On-Therapy Adverse Events (Safety Population)","timeFrame":"Start date was the first dose of investigational product and up to the day after the last dose . Post-therapy: start date was more than 1 day after the last dose and up to 30 days after last dose of investigational product up to week 364","effectByArm":[{"arm":"Eltrombopag","deltaMin":277,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":22,"exclusionCount":12},"locations":{"siteCount":110,"countries":["United States","Australia","Austria","Canada","China","Czechia","Denmark","Finland","France","Germany","Greece","Hong Kong","Italy","Netherlands","New Zealand","Pakistan","Peru","Poland","Romania","Russia","Slovakia","Slovenia","South Korea","Spain","Sweden","Taiwan","Thailand","Tunisia","Ukraine","United Kingdom","Vietnam"]},"refs":{"pmids":["29042367","23492914","23169778","22117897","21533818"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":96,"n":302},"commonTop":["Headache","Nasopharyngitis","Upper respiratory tract infection","Fatigue","Diarrhoea"]}}